1. Home
  2. AXTI vs CPRX Comparison

AXTI vs CPRX Comparison

Compare AXTI & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AXT Inc

AXTI

AXT Inc

HOLD

Current Price

$77.39

Market Cap

3.6B

Sector

Technology

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$26.22

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXTI
CPRX
Founded
1986
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
2.9B
IPO Year
1998
2006

Fundamental Metrics

Financial Performance
Metric
AXTI
CPRX
Price
$77.39
$26.22
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$24.50
$35.00
AVG Volume (30 Days)
12.8M
1.1M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.24
EPS
N/A
1.68
Revenue
$99,361,000.00
$119,072,803.00
Revenue This Year
$44.70
$9.20
Revenue Next Year
$42.23
$10.51
P/E Ratio
N/A
$15.68
Revenue Growth
31.09
16.39
52 Week Low
$1.20
$19.05
52 Week High
$83.25
$26.56

Technical Indicators

Market Signals
Indicator
AXTI
CPRX
Relative Strength Index (RSI) 63.33 63.19
Support Level $5.52 $22.24
Resistance Level N/A N/A
Average True Range (ATR) 9.68 0.61
MACD 1.90 0.15
Stochastic Oscillator 86.54 90.75

Price Performance

Historical Comparison
AXTI
CPRX

About AXTI AXT Inc

AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: